Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) EBITDA Margin: 2011-2025

Historic EBITDA Margin for Iovance Biotherapeutics (IOVA) over the last 4 years, with Sep 2025 value amounting to -140.69%.

  • Iovance Biotherapeutics' EBITDA Margin rose 1142.00% to -140.69% in Q3 2025 from the same period last year, while for Sep 2025 it was -166.31%, marking a year-over-year increase of 30691.00%. This contributed to the annual value of -240.92% for FY2024, which is 3849407.00% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported EBITDA Margin of -140.69% as of Q3 2025, which was up 25.87% from -189.78% recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' EBITDA Margin peaked at -117.48% during Q4 2024, and registered a low of -46,254.62% during Q2 2023.
  • Its 3-year average for EBITDA Margin is -11,428.64%, with a median of -286.70% in 2024.
  • Data for Iovance Biotherapeutics' EBITDA Margin shows a peak YoY spiked of 4,592,699bps (in 2024) over the last 5 years.
  • Over the past 3 years, Iovance Biotherapeutics' EBITDA Margin (Quarterly) stood at -25,156.85% in 2023, then soared by 2,503,937bps to -117.48% in 2024, then soared by 1,142bps to -140.69% in 2025.
  • Its EBITDA Margin was -140.69% in Q3 2025, compared to -189.78% in Q2 2025 and -245.76% in Q1 2025.